About TearScience
TearScience is a Healthcare company based in Morrisville (United States) founded in 2005, and was acquired by Johnson & Johnson Vision in September 2017. Devices for evaporative dry eye diagnosis and treatment are developed. TearScience has raised $150.73 million across 5 funding rounds from investors including HealthCare Royalty Partners, De Novo Ventures and Spray Venture Partners. The company has 35 employees. TearScience offers products and services including ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is TEARSCIENCE, INC. Its competitors include Bruder Healthcare, Oculeve and Tear Film Innovations; 3 of its 3 listed competitors have raised funding.
Company details
TearScience is a developer of devices that provide clinical identification and treatment of evaporative dry eye. Evaporative dry eye is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eyes natural tear film. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. The LipiFlow Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland while protecting the structures of the patients eye. TearSciences LipiFlow Thermal Pulsation System, Korb Meibomian Gland Evaluator, Lipi View products are FDA approved.
- Headquarters Morrisville, United States
- Employees 35
- Stage Acquired
- SectorsHealthcare
- Website tearscience.com
- Social LinkedIn
- Acquired by Johnson & Johnson Vision (Sep 2017)
- Legal Name Tearscience, Inc.
- Total Equity Funding$150.73M (USD)
in 5 rounds
- Latest Funding Round$19.23M (USD), Series D
Apr 2016
- InvestorsHealthCare Royalty Partners
& 7 more
- Employee Count35
- Acquired byJohnson & Johnson Vision
(Sep 2017)
Products & Services of TearScience
TearScience offers a comprehensive portfolio of products and services, including ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System.
Provides vision correction and eye health support for patients.
Offers tools to manage and prevent myopia progression.
Enables efficient ordering of products for eye care professionals.
Funding Insights of TearScience
TearScience has successfully raised a total of $150.73M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $19.23 million completed in April 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $150.73M
- Total Rounds 5
- Last Round Series D — $19.23M
- First Round $2M
(Jun 2005)
- Investors Count 7
All 5 funding rounds of TearScience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2016 | $19.23M | Series D | – | – | – |
| Feb 2013 | $70M | Series D | – | – | |
| May 2010 | $44.5M | Series C | – | De Novo Ventures, Spray Venture Partners | – |
| Jun 2007 | $15M | Series B | – | – | |
| Jun 2005 | $2M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in TearScience
TearScience has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HealthCare Royalty Partners, De Novo Ventures and Spray Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States | ||
| denovovc.com | ||||
| spraypartners.com | ||||
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors | investorgrowthcapital.com | New York, United States | ||
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
| quakerpartners.com | ||||
| eneralcatalyst.com | ||||
Eye care solutions are provided by Johnson & Johnson Vision. | jjvision.com |
Investor details for TearScience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of TearScience
4 dated milestones of TearScience across 12 years, from founding to its latest funding, stage changes and deals.
- Founded TearScience is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series D, of $19.2M.
- Exit Acquired by Johnson & Johnson Vision.
Competitors of TearScience
TearScience has 3 listed competitors in our database, 3 of them funded. They include Bruder Healthcare, Oculeve and Tear Film Innovations.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bruder.com | 1986 | Alpharetta, United States | $5M | Solutions for dry eye and pain management are developed. | ||
| oculeve.com | 2011 | San Francisco, United States | $24.94M | 19 | A non-invasive nasal device for dry eye treatment is developed. | |
| tearfilm.com | 2012 | San Diego, United States | $17.72M | Evaporative dry eye is treated through meibomian gland stimulation devices. |
Detailed competitors of TearScience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TearScience
Websites that share an audience with TearScience (tearscience.com).
Websites whose visitors overlap most with TearScience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
dryeyeshop.com | dryeyeshop.com | 100% | #512,967 | – | |
dryeyezone.com | dryeyezone.com | 77% | #1,893,356 | – | |
| theratears.com | 77% | 10.6K | #1,942,966 | View details | |
theralife.com | theralife.com | 76% | #3,478,107 | – | |
allaboutdryeye.com | allaboutdryeye.com | 76% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for TearScience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as TearScience (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TearScience
TearScience was founded in 2005.
TearScience is headquartered in Morrisville, United States.
TearScience is a funded company, having raised a total of $150.73M across 5 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jun 2005.
TearScience has 35 employees.
TearScience is a developer of devices that provide clinical identification and treatment of evaporative dry eye. Evaporative dry eye is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eyes natural tear film. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. The LipiFlow Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland while protecting the structures of the patients eye. TearSciences LipiFlow Thermal Pulsation System, Korb Meibomian Gland Evaluator, Lipi View products are FDA approved.
TearScience's top competitors include Oculeve, Tear Film Innovations and Bruder Healthcare.
TearScience offers ACUVUE Contact Lenses, Myopia Management Solutions, and Online Ordering System.
TearScience has 8 investors. Key investors include HealthCare Royalty Partners, De Novo Ventures, Spray Venture Partners, Investor Growth Capital, and eneralcatalyst.com.
TearScience operates through Tearscience, Inc..
Yes. TearScience was acquired by Johnson & Johnson Vision in September 2017.